Literature DB >> 8233490

Ototoxic liability of erythromycin and analogues.

R E Brummett1.   

Abstract

This article details clinical reports and studies of ototoxicity associated with the administration of erythromycin and its analogues. Suspected mechanisms of ototoxicity also are discussed. Ototoxicity due to erythromycin appears to be clearly dose related.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8233490

Source DB:  PubMed          Journal:  Otolaryngol Clin North Am        ISSN： 0030-6665            Impact factor:   3.346


  7 in total

Review 1.  Formulary management of macrolide antibiotics.

Authors:  D R Guay
Journal:  Pharmacoeconomics       Date:  1995-12       Impact factor: 4.981

Review 2.  Drug-induced tinnitus and other hearing disorders.

Authors:  H Seligmann; L Podoshin; J Ben-David; M Fradis; M Goldsher
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

Review 3.  Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients.

Authors:  N Principi; S Esposito
Journal:  Drug Saf       Date:  1999-01       Impact factor: 5.606

4.  Seasonal trends in tinnitus symptomatology: evidence from Internet search engine query data.

Authors:  David T Plante; David G Ingram
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-09-19       Impact factor: 2.503

Review 5.  Aminoglycoside- and Cisplatin-Induced Ototoxicity: Mechanisms and Otoprotective Strategies.

Authors:  Corné J Kros; Peter S Steyger
Journal:  Cold Spring Harb Perspect Med       Date:  2019-11-01       Impact factor: 6.915

Review 6.  Macrolide antibiotics in paediatric infectious diseases.

Authors:  D R Guay
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

7.  Ototoxic Adverse Drug Reactions: A Disproportionality Analysis Using the Italian Spontaneous Reporting Database.

Authors:  Maria Antonietta Barbieri; Giuseppe Cicala; Paola Maria Cutroneo; Eleonora Mocciaro; Laura Sottosanti; Francesco Freni; Francesco Galletti; Vincenzo Arcoraci; Edoardo Spina
Journal:  Front Pharmacol       Date:  2019-10-08       Impact factor: 5.810
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.